- Company
- Heart failure drug Entresto continues to grow rapidly
- by Kim, Jin-Gu Oct 30, 2023 05:30am
- Novartis' heart failure treatment Entresto continues to grow rapidly thanks to increased benefits. Although it has been six years since it was launched in Korea, prescriptions are increasing by more than 30% every quarter compared to last year. However, Entresto faces challenges from several successor products. Recently, Verquvo, a new heart
- Company
- Nic Horridge resigns as CEO of Roche Korea
- by Eo, Yun-Ho Oct 30, 2023 05:29am
- According to related industries, CEO Nic Horridge will step down as CEO of Roche's Korean subsidiary at the end of this month and become CEO of the Australian subsidiary. CEO Nic Horridge was appointed as CEO of Roche Korea in October 2018 and led the company for approximately five years. During his tenure, he achieved the expansion of pr
- Company
- Nephoxil can be prescribed at general hospitals
- by Eo, Yun-Ho Oct 27, 2023 05:33am
- Nephoxil, a hyperphosphatemia treatment drug, is entering the prescription range of general hospitals. According to related industries, Kyowa Kirin Korea's Nepocsil has passed the Drug Committee of about 50 hospitals across the country, including Sinchon Severance Hospital. Nephoxil was developed as a new iron-based phosphorus binder with hi
- Company
- Livtencity aims to enter the reimbursement market
- by Eo, Yun-Ho Oct 27, 2023 05:33am
- According to related industries, Takeda Pharmaceutical Korea's Livtencity submitted a benefit application in the third quarter of last year, has completed PE, and is currently submitting it to the HIRA Pharmaceutical Reimbursement Evaluation Committee. Accordingly, it remains to be seen whether an alternative treatment option can be develope
- Company
- The Key to Competitiveness is 'OS·Brain metastasis'
- by Oct 26, 2023 06:07am
- The combination therapy of major EGFR variant lung cancer treatments has yielded results at the annual conference of the European Society of Oncology (ESMO 2023). Combination therapy of Lexraza + Rybrevant has succeeded in improving major clinical evaluation indicators compared to Tagrisso monotherapy. Lexraza is a lung cancer treatment tha
- Company
- Seo Jeong-jin, targets sales of 5 trillion won for new drugs
- by Kim, Jin-Gu Oct 26, 2023 06:06am
- Seo Jeong-jin, Chairman of Celltrion Group, presented a goal to increase global new drug sales to 5 trillion won by 2030, focusing on 'Zymfentra', which was recently approved as a new drug in the United States. Chairman Seo made this announcement at a press conference held at NH Investment & Securities in Seoul on the 25th. Previously,
- Company
- Verzenio reattempts reimb for early breast cancer in KOR
- by Eo, Yun-Ho Oct 26, 2023 06:06am
- Verzenio, the first CDK4/6 inhibitor to attempt reimbursement listing for early breast cancer, has begun its second journey toward reimbursement in Korea. This attempt is being made 5 months after the first failure. The news of Lilly Korea's Verzenio (Abemaciclip) reapplication for reimbursement was made known through a written inquiry ma
- Company
- Janssen ‘will continue endeavors to the Korean society’
- by Son, Hyung-Min Oct 25, 2023 11:08am
- Janssen, which has succeeded in developing treatments in various areas including mental health, autoimmune diseases, and oncology over the past 40 years, emphasized that it will continue to contribute to Korean society by providing innovative medicines and fostering talent. On the 23rd, the company held a press conference celebrating its
- Company
- JW Pharma terminates contract after 5 yrs of atopy new drug
- by Chon, Seung-Hyun Oct 25, 2023 05:25am
- JW Pharma announced on the 20th that the technology transfer contract for 'JW1601', a treatment for atopic dermatitis, signed with Danish pharmaceutical company Leopharma, has been terminated. The company explained, “We have received a notice of termination of the contract from the Leopharma side and have agreed to return all rights.” JW1
- Company
- Combo drugs strong in the COPD treatment market
- by Son, Hyung-Min Oct 25, 2023 05:24am
- The growth of the combination drugs was notable in the chronic obstructive pulmonary disease (COPD) treatment market in Q3 this year. With major COPD treatment guidelines recommending a long-acting muscarinic antagonist (LAMA) and long-acting beta2 agonist (LABA), the prescription trend appears to have shifted toward combination drugs. In partic
